DK2794665T3 - Ikke-antikoagulative glycosaminoglycaner omfattende disaccharid-gentagelsesenhed og medicinsk anvendelse deraf - Google Patents

Ikke-antikoagulative glycosaminoglycaner omfattende disaccharid-gentagelsesenhed og medicinsk anvendelse deraf

Info

Publication number
DK2794665T3
DK2794665T3 DK12858809.2T DK12858809T DK2794665T3 DK 2794665 T3 DK2794665 T3 DK 2794665T3 DK 12858809 T DK12858809 T DK 12858809T DK 2794665 T3 DK2794665 T3 DK 2794665T3
Authority
DK
Denmark
Prior art keywords
disaccharid
glycosaminoglycanes
anticoagulative
comprehensive
repeating unit
Prior art date
Application number
DK12858809.2T
Other languages
English (en)
Inventor
Hans-Peter Ekre
Per-Olov Eriksson
Ulf Lindahl
Erik Holmer
Original Assignee
Dilafor Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48668970&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2794665(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dilafor Ab filed Critical Dilafor Ab
Application granted granted Critical
Publication of DK2794665T3 publication Critical patent/DK2794665T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
DK12858809.2T 2011-12-19 2012-12-19 Ikke-antikoagulative glycosaminoglycaner omfattende disaccharid-gentagelsesenhed og medicinsk anvendelse deraf DK2794665T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161577223P 2011-12-19 2011-12-19
PCT/SE2012/051433 WO2013095279A1 (en) 2011-12-19 2012-12-19 Non anti-coagulative glycosaminoglycans comprising repeating disaccharide unit and their medical use

Publications (1)

Publication Number Publication Date
DK2794665T3 true DK2794665T3 (da) 2018-01-29

Family

ID=48668970

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12858809.2T DK2794665T3 (da) 2011-12-19 2012-12-19 Ikke-antikoagulative glycosaminoglycaner omfattende disaccharid-gentagelsesenhed og medicinsk anvendelse deraf

Country Status (28)

Country Link
US (1) US9475888B2 (da)
EP (1) EP2794665B1 (da)
JP (2) JP6543467B2 (da)
KR (1) KR102135485B1 (da)
CN (1) CN104144950B (da)
AU (1) AU2012354229B2 (da)
BR (1) BR112014014454B1 (da)
CA (1) CA2856492C (da)
CL (1) CL2014001651A1 (da)
CO (1) CO7061069A2 (da)
CY (1) CY1119899T1 (da)
DK (1) DK2794665T3 (da)
ES (1) ES2656613T3 (da)
HK (1) HK1202883A1 (da)
HR (1) HRP20180124T1 (da)
HU (1) HUE036523T2 (da)
IL (1) IL232905A (da)
LT (1) LT2794665T (da)
ME (1) ME02994B (da)
MX (1) MX351104B (da)
NO (1) NO2904345T3 (da)
PL (1) PL2794665T3 (da)
PT (1) PT2794665T (da)
RS (1) RS56874B1 (da)
RU (1) RU2617764C2 (da)
SI (1) SI2794665T1 (da)
WO (1) WO2013095279A1 (da)
ZA (1) ZA201403640B (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013095215A1 (en) 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
WO2013147690A1 (en) * 2012-03-26 2013-10-03 Dilafor Ab Method for treatment of labor arrest
CN104203256B (zh) * 2012-03-26 2017-11-24 迪乐方有限责任公司 用于引产的包含硫酸化的葡糖胺聚糖的联合治疗
WO2013169194A1 (en) * 2012-05-08 2013-11-14 Dilafor Ab Treatment of postpartum haemorrhage with chemically modified heparin or heparan sulphate and a uterotonic agent
GB2515315A (en) 2013-06-19 2014-12-24 Dilafor Ab New Processes
CN103788222B (zh) * 2014-01-08 2016-08-31 中国科学院昆明植物研究所 Fuc3S4S取代的低聚糖胺聚糖及其制备方法
MX2016014202A (es) * 2014-04-30 2017-05-03 Agency Science Tech & Res Sulfatos de heparan.
CN108424474B (zh) * 2017-02-15 2023-07-25 清华大学 去抗凝肝素衍生物及其用于炎症性肠病的治疗
WO2021165240A1 (en) 2020-02-17 2021-08-26 Dilafor Ab Tafoxiparin for the treatment of preeclampsia
WO2023213788A1 (en) 2022-05-03 2023-11-09 Dilafor Ab New medical use of tafoxiparin
EP4272749A1 (en) 2022-05-03 2023-11-08 Dilafor AB New medical use of tafoxiparin

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1136620A (en) 1979-01-08 1982-11-30 Ulf P.F. Lindahl Heparin fragments having selective anticoagulation activity
JPS63246396A (ja) * 1987-03-31 1988-10-13 Shiseido Co Ltd モノクロ−ナル抗体
FR2614026B1 (fr) * 1987-04-16 1992-04-17 Sanofi Sa Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
SE9002550D0 (sv) * 1990-08-01 1990-08-01 Kabivitrum Ab Heparinfragment
SE9003181D0 (sv) 1990-10-04 1990-10-04 Kabivitrum Ab Use of heparin fraction
US5250519A (en) 1991-03-29 1993-10-05 Glycomed Incorporated Non-anticoagulant heparin derivatives
US5280016A (en) 1991-03-29 1994-01-18 Glycomed Incorporated Non-anticoagulant heparin derivatives
JPH0532703A (ja) * 1991-07-26 1993-02-09 Terumo Corp 低分子量ヘパリン誘導体の製造法
AU5442594A (en) * 1992-10-13 1994-05-09 Virginia Commonwealth University Use of non-anticoagulant heparin for treating ischemia/reperfusion injury
US5527785A (en) 1993-05-14 1996-06-18 The Regents Of The University Of California Selectin receptor modulating compositions
EP0735050B1 (en) * 1995-03-31 2002-09-25 Hamilton Civic Hospitals Research Development, Inc. Compositions for inhibiting thrombogenesis
US5744457A (en) * 1995-03-31 1998-04-28 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US5993810A (en) 1996-03-15 1999-11-30 Lebovitz; Shamir Israel Method of softening or ripening the cervix of a female mammal using collagenase
US5767269A (en) * 1996-10-01 1998-06-16 Hamilton Civic Hospitals Research Development Inc. Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics
JP4203611B2 (ja) 1996-10-15 2009-01-07 生化学工業株式会社 子宮頸管熟化剤
GB9711443D0 (en) * 1997-06-03 1997-07-30 Leo Pharm Prod Ltd Chemical suppositions
JP3342007B2 (ja) * 1997-11-20 2002-11-05 郁男 山科 低分子ヘパリン修飾体及び皮膚潰瘍治療剤
US6596705B1 (en) 1998-02-09 2003-07-22 The Regents Of The University Of California Inhibition of L-selectin and P-selection mediated binding using heparin
US6498246B1 (en) 1998-02-26 2002-12-24 Seikagaku Corporation Glycosaminoglycan derivatives and processes for preparing same
US6028061A (en) 1998-06-18 2000-02-22 Children's Medical Center Corp Angiogenesis inhibitors and use thereof
ATE270677T1 (de) * 1998-07-31 2004-07-15 Seikagaku Kogyo Co Ltd Neues glycosaminoglycan und dieses enthaltendes arzneimittel
MXPA01002022A (es) * 1998-08-26 2002-04-24 Collaborative Group Ltd Receptor para beta-(1,3-)glucano soluble acuoso, no derivado.
CA2377734A1 (en) * 1999-06-30 2001-01-11 Hamilton Civic Hospitals Research Development, Inc. Heparin compositions that inhibit clot associated coagulation factors
JP4897991B2 (ja) * 1999-07-23 2012-03-14 ラボラトリオス ファルマセウティコス ロビ ソシエダッド アノニマ 超低分子量ヘパリン組成物
IT1316986B1 (it) 2000-01-25 2003-05-26 Sigma Tau Ind Farmaceuti Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.
JP4585072B2 (ja) * 2000-02-29 2010-11-24 扶桑薬品工業株式会社 ヘパリン解重合法、解重合ヘパリン、その誘導体および医薬組成物
WO2002023190A2 (en) * 2000-09-12 2002-03-21 Massachusetts Institute Of Technology Methods and products related to low molecular weight heparin
SE521676C2 (sv) * 2002-01-02 2003-11-25 Dilafor Ab Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
AU2003230985A1 (en) 2002-04-18 2003-11-03 Stephen H. Embury Method and composition for preventing pain in sickle cell patients
US8071569B2 (en) 2002-09-20 2011-12-06 Mousa Shaker A Oxidized heparin fractions and their use in inhibiting angiogenesis
JP2005106694A (ja) * 2003-09-30 2005-04-21 Mochida Pharmaceut Co Ltd 敗血症早期検出及び重篤度評価
EP1582531A1 (en) 2004-03-24 2005-10-05 Aventis Pharma S.A. Process for oxidizing unfractionated heparins and detecting presence or absence of glycoserine in heparin and heparin products
US20060040896A1 (en) * 2004-08-18 2006-02-23 Paringenix, Inc. Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity
US7741311B2 (en) 2005-01-03 2010-06-22 Shaker Mousa Composition and method for treating occlusive vascular diseases, nerve regeneration, and wound healing
CA2616166A1 (en) * 2005-07-22 2007-02-01 The Regents Of The University Of California Heparin compositions and selectin inhibition
EP1906975A4 (en) 2005-07-22 2010-10-06 Trf Pharma Inc METHOD FOR THE TREATMENT OF SICKLE CELL DISEASE AND CONSEQUENCES OF SICKLE CELL DISEASE
EP3168618B1 (en) * 2006-04-04 2018-11-21 Singulex, Inc. Highly sensitive methods for analysis of troponin
WO2007140231A2 (en) * 2006-05-25 2007-12-06 Momenta Pharmaceutical, Inc. Low molecular weight heparin composition and uses thereof
WO2009007224A1 (en) * 2007-07-10 2009-01-15 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Low molecular weight heparin derivatives having neuroprotective activity
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
WO2009059284A2 (en) 2007-11-02 2009-05-07 Momenta Pharmaceuticals, Inc. Non-anticoagulant polysaccharide compositions
EP2207811B1 (en) * 2007-11-02 2017-01-04 Momenta Pharmaceuticals, Inc. Non-anticoagulant polysaccharide compositions
US8592393B2 (en) * 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US8445436B2 (en) 2007-12-03 2013-05-21 Florida State University Research Foundation, Inc. Oxytocin and melatonin compositions and associated methods for inducing labor
KR101594552B1 (ko) 2008-04-04 2016-02-17 유니버시티 오브 유타 리서치 파운데이션 알킬화된 반합성 글리코사미노글리코산 에테르 및 이의 제조 및 사용 방법
WO2010111570A1 (en) * 2009-03-27 2010-09-30 E. I. Du Pont De Nemours And Company Polyglycerol aldehydes
DK2419736T3 (da) 2009-04-16 2014-04-22 Momenta Pharmaceuticals Inc Fremgangsmåder til vurdering af aktivitet af en polysaccharidsammensætning
WO2011000032A1 (en) 2009-06-30 2011-01-06 Walter And Eliza Hall Institute Of Medical Research Sulfated polysaccharides having antiplasmodial activity and methods and products for identifying antiplasmodial activity
EA201290069A1 (ru) * 2009-07-31 2012-07-30 Байер Хелскер Ллс Модифицированные полипептиды фактора ix и их применения
CA2782863A1 (en) * 2009-12-22 2011-06-30 Lifebond Ltd Modification of enzymatic crosslinkers for controlling properties of crosslinked matrices
WO2013095215A1 (en) 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
CN104203256B (zh) 2012-03-26 2017-11-24 迪乐方有限责任公司 用于引产的包含硫酸化的葡糖胺聚糖的联合治疗
WO2013147690A1 (en) 2012-03-26 2013-10-03 Dilafor Ab Method for treatment of labor arrest

Also Published As

Publication number Publication date
IL232905A0 (en) 2014-07-31
PL2794665T3 (pl) 2018-04-30
CO7061069A2 (es) 2014-09-19
US20150011505A1 (en) 2015-01-08
KR102135485B1 (ko) 2020-07-17
EP2794665A4 (en) 2015-08-26
RU2617764C2 (ru) 2017-04-26
PT2794665T (pt) 2018-01-24
BR112014014454B1 (pt) 2021-03-09
AU2012354229B2 (en) 2016-12-01
JP2015500388A (ja) 2015-01-05
RU2014129816A (ru) 2016-02-20
RS56874B1 (sr) 2018-04-30
ZA201403640B (en) 2017-06-28
EP2794665A1 (en) 2014-10-29
ME02994B (me) 2018-10-20
AU2012354229A1 (en) 2014-06-05
WO2013095279A1 (en) 2013-06-27
HK1202883A1 (en) 2015-10-09
CY1119899T1 (el) 2018-06-27
CA2856492C (en) 2017-01-10
HRP20180124T1 (hr) 2018-02-23
US9475888B2 (en) 2016-10-25
IL232905A (en) 2017-02-28
CL2014001651A1 (es) 2014-10-10
MX2014007122A (es) 2015-03-05
KR20140113652A (ko) 2014-09-24
MX351104B (es) 2017-10-02
CN104144950A (zh) 2014-11-12
SI2794665T1 (en) 2018-03-30
NO2904345T3 (da) 2018-07-21
HUE036523T2 (hu) 2018-07-30
LT2794665T (lt) 2017-12-27
ES2656613T3 (es) 2018-02-27
EP2794665B1 (en) 2017-11-22
JP6543467B2 (ja) 2019-07-10
BR112014014454A2 (pt) 2017-06-13
CA2856492A1 (en) 2013-06-27
JP2018111825A (ja) 2018-07-19
CN104144950B (zh) 2017-09-05

Similar Documents

Publication Publication Date Title
DK2794665T3 (da) Ikke-antikoagulative glycosaminoglycaner omfattende disaccharid-gentagelsesenhed og medicinsk anvendelse deraf
PH12014501387A1 (en) Low anticoagulant heparins
TN2015000283A1 (fr) Functionalized exendin-4 derivatives
EA201390600A1 (ru) Терапевтические наночастицы с сополимерами с большим молекулярным весом
WO2012008722A3 (ko) 조직 증강용 충전 조성물
MY156938A (en) Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application
MX2014007934A (es) Composicion de farmaco de carbohidrato novedoso para el tratamiento de enfermedades humanas.
WO2009024677A3 (fr) Utilisation d ' acide hyaluronique pour la preparation de compositions destinees a l' amelioration de la fonction de protection de la peau, de l' oeil et des muqueuses
WO2013106385A3 (en) System and methods for determining tissue elasticity
SI2429515T1 (sl) Nova zdravila za topično uporabo na osnovi sulfatirane hialuronske kisline kot sredstvo za aktiviranje ali inhibiranje citokinske aktivnosti
EA201190283A1 (ru) Мультивалентный адъювантный дисплей
GB2482817A (en) Novel use
PH12014502680A1 (en) Polysaccharide compositions and methods of use
WO2018056937A3 (en) Nanofibrous adhesion barrier
TN2012000581A1 (en) Piperidinyl compound as a modulator of chemokine receptor activity
JP2007126453A5 (da)
IN2015DN02358A (da)
WO2013160349A3 (en) Cosmetic composition comprising a phosphorylated oligosaccharide and a polysaccharide
WO2010149641A3 (en) Pharmaceutical agent
MX347620B (es) Derivados de sulfonilaminopirrolidinona, su preparacion y aplicacion terapeutica.
TR201908669T4 (tr) N-desülfatlanmış glikozaminoglikanların türevleri ve ilaç olarak kullanımı.
WO2013050697A3 (fr) Utilisation de glucanes obtenus a partir de prunus persica comme agent cosmetique anti-age
BR112013009185A2 (pt) uso de mexiprostil no tratamento de doença inflamatória intestinal e/ou de síndrome do intestino irritável.
RS54013B1 (en) HIGH-ELASTIC GELS IN OPTAMOLOGICAL SURGERY
UA114085C2 (xx) Біотехнологічний хондроїтинсульфат, сульфатований в положенні 4 або 6 на його полісахаридному ланцюзі, і спосіб його отримання